Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00214552 · ClinicalTrials.gov registry record · Phase 3
Evaluate the Effects on Asthma Control of Rabeprazole Given Twice Daily in Subjects With Asthma.
A Phase 3 study of Asthma and Gastroesophageal Reflux Disease, sponsored by Associated Scientists to Help Minimize Allergies.
- Completed
- Registry status
- Phase 3
- Development phase
- 80
- Enrollment target
- 2
- Study locations
NCT00214552: Completed Phase 3 study of Asthma and Gastroesophageal Reflux Disease, sponsored by Associated Scientists to Help Minimize Allergies.
NCT00214552 is a Phase 3 study of Asthma and Gastroesophageal Reflux Disease that has completed, run by Associated Scientists to Help Minimize Allergies. The registered enrollment target is 80 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00214552, a Phase 3 study of Asthma and Gastroesophageal Reflux Disease, has completed, sponsored by Associated Scientists to Help Minimize Allergies.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 80 participants
- Enrollment target
- 2
- Study locations
Study Summary
The hypothesis for this study is that potent anti-secretory therapy with high dose PPI improves asthma control regardless of either asthma severity or the presence of GERD symptoms.
Conditions Studied
Interventions
- DRUG rabeprazole
Study Locations (2)
Washington
- ASTHMA, Inc. - Richland
- ASTHMA, Inc. - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2002-09 |
| Est. Completion | 2005-03 |
| Phase | Phase 3 |
What the finished NCT00214552 record still lists
NCT00214552 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Asthma appearing as the primary indexed condition, and to 1 intervention - of which rabeprazole is the first listed.
NCT00214552 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT00214552 about?
NCT00214552 is a clinical study titled "Evaluate the Effects on Asthma Control of Rabeprazole Given Twice Daily in Subjects With Asthma.". The hypothesis for this study is that potent anti-secretory therapy with high dose PPI improves asthma control regardless of either asthma severity or the presence of GERD symptoms.
What is the current status of trial NCT00214552?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 80 participants. The study started on 2002-09. Estimated completion is 2005-03.
What conditions does trial NCT00214552 study?
This clinical trial studies the following conditions: Asthma, Gastroesophageal Reflux Disease.
What interventions are being tested in trial NCT00214552?
The interventions under investigation include: rabeprazole (DRUG).
Who is sponsoring clinical trial NCT00214552?
This trial is sponsored by Associated Scientists to Help Minimize Allergies, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00214552 being conducted?
This trial has 2 study locations across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00214552's enrollment target sits among peer trials
80 226th of 374 higher than 147 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
RECRUITING · Phase 3
-
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
RECRUITING · Phase 3
-
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
RECRUITING · Phase 3
-
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia